Botulinum Antitoxin Patient Registry for the Evaluation of Safety and Clinical Outcomes of Pediatric and Adult Patients Following BAT Treatment for Confirmed or Suspected Exposure to Botulinum Toxin
Phase of Trial: Phase IV
Latest Information Update: 13 Apr 2016
At a glance
- Drugs Botulinum-antitoxin (Primary)
- Indications Botulism
- Focus Adverse reactions
- Sponsors Cangene Corporation
- 04 Apr 2016 Planned End Date changed from 1 Apr 2018 to 1 Dec 2017 as reported by ClinicalTrials.gov.
- 04 Apr 2016 Planned primary completion date changed from 1 Oct 2017 to 1 Jun 2017 as reported by ClinicalTrials.gov.
- 24 Dec 2014 Planned primary completion date changed from 1 Jan 2017 to 1 Oct 2017, as reported by ClinicalTrials.gov.